Crescita Therapeutics Inc - Asset Resilience Ratio
Crescita Therapeutics Inc (CTX) has an Asset Resilience Ratio of 38.72% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check CTX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Crescita Therapeutics Inc's Asset Resilience Ratio has changed over time. See Crescita Therapeutics Inc (CTX) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Crescita Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Crescita Therapeutics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$8.31 Million | 38.72% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$8.31 Million | 38.72% |
Asset Resilience Insights
- Very High Liquidity: Crescita Therapeutics Inc maintains exceptional liquid asset reserves at 38.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Crescita Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Crescita Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Crescita Therapeutics Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Crescita Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 42.58% | CA$9.27 Million ≈ $6.71 Million |
CA$21.78 Million ≈ $15.75 Million |
+4.42pp |
| 2023-12-31 | 38.17% | CA$9.39 Million ≈ $6.79 Million |
CA$24.60 Million ≈ $17.79 Million |
+8.99pp |
| 2022-12-31 | 29.17% | CA$8.31 Million ≈ $6.01 Million |
CA$28.48 Million ≈ $20.60 Million |
-10.28pp |
| 2021-12-31 | 39.45% | CA$11.41 Million ≈ $8.25 Million |
CA$28.92 Million ≈ $20.92 Million |
-14.00pp |
| 2020-12-31 | 53.45% | CA$14.34 Million ≈ $10.37 Million |
CA$26.83 Million ≈ $19.41 Million |
+18.69pp |
| 2019-12-31 | 34.76% | CA$9.33 Million ≈ $6.75 Million |
CA$26.84 Million ≈ $19.41 Million |
+3.42pp |
| 2018-12-31 | 31.34% | CA$8.64 Million ≈ $6.25 Million |
CA$27.57 Million ≈ $19.94 Million |
+0.07pp |
| 2017-12-31 | 31.28% | CA$7.06 Million ≈ $5.11 Million |
CA$22.57 Million ≈ $16.32 Million |
-11.40pp |
| 2016-12-31 | 42.68% | CA$18.36 Million ≈ $13.28 Million |
CA$43.02 Million ≈ $31.12 Million |
+42.51pp |
| 2015-12-31 | 0.17% | CA$2.00K ≈ $1.45K |
CA$1.19 Million ≈ $859.38K |
+0.05pp |
| 2014-12-31 | 0.12% | CA$2.00K ≈ $1.45K |
CA$1.64 Million ≈ $1.18 Million |
-- |
About Crescita Therapeutics Inc
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhanc… Read more